Media headlines about Ra Pharmaceuticals (NASDAQ:RARX) have trended somewhat positive on Saturday, according to Accern. The research group identifies negative and positive news coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Ra Pharmaceuticals earned a news sentiment score of 0.11 on Accern’s scale. Accern also gave headlines about the company an impact score of 47.4132759101521 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Ra Pharmaceuticals (NASDAQ RARX) traded down $0.12 during trading hours on Friday, reaching $8.49. 65,723 shares of the company’s stock were exchanged, compared to its average volume of 172,785. The firm has a market cap of $194.82, a P/E ratio of -3.44 and a beta of 6.29. Ra Pharmaceuticals has a twelve month low of $7.15 and a twelve month high of $27.84.
Ra Pharmaceuticals (NASDAQ:RARX) last released its earnings results on Thursday, November 9th. The company reported ($0.68) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.06). analysts forecast that Ra Pharmaceuticals will post -2.46 earnings per share for the current fiscal year.
RARX has been the subject of several recent research reports. Zacks Investment Research raised Ra Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, September 19th. Jefferies Group reissued a “buy” rating and set a $25.00 target price on shares of Ra Pharmaceuticals in a research report on Thursday, September 28th. Credit Suisse Group increased their target price on shares of Ra Pharmaceuticals from $19.00 to $23.00 and gave the company an “outperform” rating in a research report on Friday, November 10th. BMO Capital Markets reissued an “outperform” rating and set a $34.00 target price (up previously from $31.00) on shares of Ra Pharmaceuticals in a research report on Monday, December 4th. Finally, Royal Bank of Canada reissued a “buy” rating and set a $18.00 target price on shares of Ra Pharmaceuticals in a research report on Tuesday, December 5th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company. Ra Pharmaceuticals has an average rating of “Buy” and an average target price of $21.90.
About Ra Pharmaceuticals
Ra Pharmaceuticals, Inc is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutics for diseases of complement dysregulation and a range of orphan indications. It utilizes small molecules and peptide approaches to address pathological targets in the complement cascade.
Receive News & Ratings for Ra Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.